Corbus Pharmaceuticals
CRBP
69 hedge funds and large institutions have $101M invested in Corbus Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 18 increasing their positions, 4 reducing their positions, and 18 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 4
83% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 18
28% more funds holding
Funds holding: 54 → 69 (+15)
0.1% more ownership
Funds ownership: 0.96% → 1.06% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $116M → $101M (-$15M)
19% less call options, than puts
Call options by funds: $2.19M | Put options by funds: $2.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.72M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.81M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.01M |
| 5 |
AG
Artal Group
Luxembourg
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.02M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.29M |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$1.17M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.04M |
CRBP Hedge Fund Activity: Q2 2017 in Review
69 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2017, worth a combined $101M — down 13% from $116M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CRBP positions and 18 closed out — a net gain of 15 holders — while 18 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $11.7M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $13.9M sold.
- 69 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2017, up from 54 in Q1 2017.
- Funds reported $101M of Corbus Pharmaceuticals stock for Q2 2017, down 13% quarter-over-quarter.
- 33 funds opened new Corbus Pharmaceuticals positions in Q2 2017 and 18 closed out, a net change of +15 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2017 was BlackRock, an estimated $11.7M added.
- The largest Corbus Pharmaceuticals seller in Q2 2017 was Cormorant Asset Management, an estimated $13.9M sold.
Based on aggregated 13F filings for Q2 2017.